regulatory
confidence high
sentiment positive
materiality 0.70
Inogen receives FDA 510(k) clearance for SIMEOX 200, triggering $13M milestone payment
Inogen Inc
- FDA cleared SIMEOX 200 for airway clearance and bronchial drainage in patients with chronic lung diseases.
- Clearance triggers $13M cash earnout payment to Physio-Assist sellers under July 2023 purchase agreement.
- Device targets mucus hypersecretion in Bronchiectasis, COPD, Cystic Fibrosis, and Primary Ciliary Dyskinesia.
- Inogen plans limited U.S. launch in 2025 via existing HCP, B2B, and direct-to-patient channels.